APA (7th ed.) Citation

DL, M., R, L., HY, C., D, J., O, B., S, M., . . . JM, J. (2025). Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025. MMWR. Morbidity and mortality weekly report, 74(32), 508. https://doi.org/10.15585/mmwr.mm7432a3

Chicago Style (17th ed.) Citation

DL, Moulia, et al. "Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025." MMWR. Morbidity and Mortality Weekly Report 74, no. 32 (2025): 508. https://doi.org/10.15585/mmwr.mm7432a3.

MLA (9th ed.) Citation

DL, Moulia, et al. "Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025." MMWR. Morbidity and Mortality Weekly Report, vol. 74, no. 32, 2025, p. 508, https://doi.org/10.15585/mmwr.mm7432a3.